Menu

Blog

Page 6760

Apr 12, 2020

Inhibition of SARS-coronavirus infection in vitro

Posted by in category: biotech/medical

2004…

https://www.ijidonline.com/article/S1201-9712(04)00052-9/fulltext

“During the SARS epidemic, Chen and colleagues included inhalation of NO gas in the treatment of a number of SARS patients. Medicinal NO gas, a gaseous blend of nitric oxide (0.8%) and nitrogen (99.2%), was given for three days or longer, initially at 30 ppm and then at 20 and 10 ppm on the second and third day (unpublished data). Their findings suggest not only an immediate improvement of oxygenation but also a lasting effect on the disease itself after termination of inhalation of NO.

Continue reading “Inhibition of SARS-coronavirus infection in vitro” »

Apr 12, 2020

Does Nitric Oxide Play a Critical Role in Viral Infections?

Posted by in categories: biotech/medical, neuroscience

Many virus infections elicit vigorous host immune responses, both innate and acquired. The immune responses are frequently successful in controlling and then clearing the virus, using both cellular effectors such as natural killer (NK) cells and cytolytic T lymphocytes and soluble factors such as interferons (IFNs). However, some immune responses lead to pathologic changes or are unable to prevent the pathogen’s growth. This review will not be devoted to the different strategies viruses have taken to promote their transmission or survival but rather to one aspect of the innate immune response to infection: the role of nitric oxide (NO) in the antiviral repertoire. Recently, data from many laboratories, using both RNA and DNA viruses in experimental systems, have implicated a role for NO in the immune response. The data do not indicate a magic bullet for all systems but suggest that NO may inhibit an early stage in viral replication and thus prevent viral spread, promoting viral clearance and recovery of the host.

The earliest host responses to viral infections are nonspecific and involve the induction of cytokines, among them, IFNs and tumor necrosis factor alpha (TNF-α). Gamma IFN (IFN-γ) and TNF-α have both been shown to be active in many cell types and induce cascades of downstream mediators (reviewed in references , , and ). Others have found that NO synthase type 2 (NOS-2, iNOS) is an IFN-γ-inducible protein in macrophages, requiring IRF-1 as a transcription factor (, ). We have observed that the isoform expressed in neurons, NOS-1, is IFN-γ, TNF-α, and interleukin-12 (IL-12) inducible (). Thus, NOS falls into the category of IFN-inducible proteins, activated during innate immune responses.

NO is produced by the enzymatic modification of l-arginine to l-citrulline and requires many cofactors, including tetrahydrobiopterine, calmodulin, NADPH, and O2. NO rapidly reacts with proteins or with H2O2 to form ONOO, peroxynitrite, which is highly toxic (Fig. (Fig.1). 1 ). NO also readily binds heme proteins, including Hb and its own enzyme.

Apr 12, 2020

US Army develops drones fired from grenade launchers

Posted by in category: drones

New system uses small camera drones fired from greande launchers to provide advanced sueveullance for troops. Two models each have 90-minute battery life.

Apr 12, 2020

For First Time in History, AI Learns to Translate Silent Human Brain Activity into Text for Locked-In Syndrome Patients

Posted by in categories: biotech/medical, information science, robotics/AI

Neuroscientists have just created an artificially intelligent algorithm that detects human brain activity and translates it into English sentences—and they said it was the first time such translations could be done on a 1:1 speed with natural human speech; faster-than-light.

Apr 12, 2020

Why Some Doctors Are Now Moving Away From Ventilator Treatments for Coronavirus Patients

Posted by in categories: biotech/medical, health

#Repost “Some doctors are experimenting with adding nitric oxide to the mix, to help improve blood flow and oxygen to the least damaged parts of the lungs.”

Ironically enough nitric oxide improves blood oxygen flow, and also clears blood clots. Some patients who survive COVID19 have clots in the blood vessels in their lungs. We just have to wait and see.


(NEW YORK) — As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can. The reason: Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients.

Continue reading “Why Some Doctors Are Now Moving Away From Ventilator Treatments for Coronavirus Patients” »

Apr 12, 2020

5G dangers: mmWave microwaves and other health claims debunked

Posted by in categories: health, internet

Health hysteria has plagued the communications industry for decades despite the lack of evidence. 5G is no different.

Apr 12, 2020

Scientists create mutant enzyme that recycles plastic bottles in hours

Posted by in categories: innovation, sustainability

A mutant bacterial enzyme that breaks down plastic bottles for recycling in hours has been created by scientists.

The enzyme, originally discovered in a compost heap of leaves, reduced the bottles to chemical building blocks that were then used to make high-quality new bottles. Existing recycling technologies usually produce plastic only good enough for clothing and carpets.

The company behind the breakthrough, Carbios, said it was aiming for industrial-scale recycling within five years. It has partnered with major companies including Pepsi and L’Oréal to accelerate development. Independent experts called the new enzyme a major advance.

Apr 12, 2020

My Girlfriend Is a Chatbot

Posted by in categories: biotech/medical, robotics/AI

Quarantine amid coronavirus could boost the nascent practice of seeking romance and friendship from artificial intelligence.

Apr 12, 2020

Remdesivir Improves COVID-19 Symptoms in 68% of Patients in Early Study

Posted by in category: biotech/medical

An early analysis of remdesivir, a drug developed by pharmaceutical firm Gilead, has shown that it may have improved severe symptoms of COVID-19 in 68% of patients after 18 days.

For the Gilead-funded study, doctors recruited 61 patients hospitalized with COVID-19 with oxygen saturation of 94% or less while breathing ambient air or receiving oxygen support. To receve remdesivir on a compassionate use basis (a program allowing the use of unapproved medicines when no other treatment options are available), on the first day of treatment, patients were administered 200mg of remesdevir, and then 100 mg daily on the remaining 9 days of treatment.

Continue reading “Remdesivir Improves COVID-19 Symptoms in 68% of Patients in Early Study” »

Apr 12, 2020

FDA approves blood purification device to treat coronavirus

Posted by in category: biotech/medical

The FDA issued the emergency authorization to use blood purification devices to treat coronavirus patients on Friday.